1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
Abbott Laboratories

Abbott Laboratories

ABT.TO
Abbott LaboratoriesCA flagToronto Stock Exchange
17.68
CAD
-0.38
- -
30.59BMarket Cap
Abbott Laboratories
ABT.TO
(Toronto Stock Exchange)

Recent

price

17.68

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
2.96
1.77
1.57
1.65
1.75
1.8
1.84
2.04
2.27
2.35
2.54
3.18
3.27
3.01
3.15
3.32
2.54
Revenue per Share
0.39
0.39
0.49
0.22
0.2
0.39
0.12
0.04
0.18
0.27
0.33
0.52
0.52
0.43
1.01
0.49
0.34
Basic EPS, GAAP
0.65
0.62
0.62
0.18
0.22
0.16
0.18
0.33
0.36
0.33
0.42
0.64
0.58
0.38
0.48
0.55
0.44
Free Cash Flow per Basic Share
0.22
0.24
0.26
0.07
0.12
0.13
0.14
0.14
0.15
0.17
0.19
0.24
0.25
0.27
0.29
0.31
0.24
Dividend per Share
14.66
15.56
16.95
16.26
14.27
14.4
13.94
17.72
17.39
17.64
18.51
20.29
21.11
22.26
27.52
30.02
- -
Book Value per Share
-3.49
-0.8
1.5
6.24
3.49
4.08
5.65
-8.37
-6.65
-5.18
-3.24
-0.1
1.98
3.52
10.34
13
- -
Tangible Book Value per Share
11,891
12,071
12,119
11,900
11,592
11,320
11,321
13,402
13,495
13,548
13,615
13,560
13,358
13,329
13,311
13,349
13,373
Basic Weighted Avg Shares
35,167
21,407
19,050
19,657
20,247
20,405
20,853
27,390
30,578
31,904
34,608
43,075
43,653
40,109
41,950
44,328
33,992
Sales/Revenue/Turnover
18.2
7.61
7.14
10.85
12.84
14.05
14.51
5.71
11.94
14.21
15.48
19.56
19.16
16.15
16.27
18.17
16.63
Operating Margin (%)
2,624
3,044
2,782
1,719
1,548
1,472
1,353
3,021
3,278
3,014
3,327
3,538
3,267
3,243
3,218
3,116
2,386
Depreciation Expense
4,626
4,728
5,963
2,576
2,284
4,423
1,400
477
2,368
3,687
4,495
7,071
6,933
5,723
13,402
6,524
4,497
Net Income, GAAP
19.02
8.9
- -
2.6
31.65
18.13
24.77
84.18
18.76
9.57
10
13.88
16.53
14.12
- -
22.94
24.89
Effective Tax Rate (%)
13.15
22.09
31.3
13.1
11.28
21.68
6.71
1.74
7.74
11.56
12.99
16.42
15.88
14.27
31.95
14.72
13.23
Profit Margin (%)
5,055
8,289
18,043
9,740
3,089
4,969
20,116
11,235
5,620
4,804
8,534
11,134
9,735
8,829
9,499
9,500
- -
Working Capital
12,524
12,040
18,085
3,388
3,393
5,871
20,681
27,210
19,359
17,416
19,429
18,252
15,465
14,548
13,521
10,827
- -
LT Debt
22,765
24,526
26,813
25,267
21,639
21,326
20,717
31,098
30,722
31,301
33,003
36,024
36,905
38,827
47,901
52,771
- -
Total Equity
12.58
3.59
- -
5.24
5.81
7.84
6.23
0.49
5.43
8.17
9.4
13.51
12.77
10.21
- -
9.56
13.23
Return on Invested Capital (%)
12.52
12.39
- -
6.87
7.79
15.24
4.72
1.22
5.56
8.54
9.7
13.99
13.5
11.5
- -
10.66
14.97
Return on Capital (%)
20.32
20.07
23.31
9.93
9.78
20.7
6.71
1.85
7.71
11.97
14.08
20.62
19.13
15.2
31.07
13.07
17.79
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
3,033
4,409
- -
LT Borrowings
9,896
29,638
- -
LT Finance Leases
931
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,737
1,742
1,742
Market Capitalization
28,188
22,502
19,573

Working Capital

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
25,996
25,508
- -
Cash, Cash Equivalents & STI
8,939
7,295
- -
Accounts Receivable, Net
7,929
8,210
- -
Inventories
6,488
6,989
- -
Total Current Liabilities
16,496
18,377
- -
Payables & Accruals
13,463
13,968
- -
ST Debt
3,033
4,409
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
10.37%
10.07%
10.17%
Free Cash Flow
20.29%
9.63%
16.44%
Net Income, GAAP
46.05%
24.15%
-51.32%
Sales/Revenue/Turnover
8.6%
5.59%
5.67%
Total Cash Common Dividend
11.24%
10.21%
7.3%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
9,964
10,377
10,635
10,974
41,950
2025
10,358
11,142
11,369
11,459
44,328
2026
11,164
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.09
0.1
0.12
0.69
1.01
2025
0.1
0.13
- -
0.13
0.49
2026
0.08
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.07
0.07
0.07
0.07
0.29
2025
0.08
0.08
- -
0.08
0.31
2026
0.08
- -
- -
- -
- -
Similar Companies
SofWave Medical Ltd. (SOFW.TA)
Olympus Corporation (7733.T)
Ludwig Enterprises, Inc. (LUDG)
Stratec SE (STSEY)
Edwards Lifesciences Corporation (EW)
Ambu A/S (AMBU-B.CO)
Business
Abbott Laboratories is a global healthcare company that discovers, develops, manufactures and sells a broad portfolio of medical products and services worldwide, with operations organized across Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Medical Devices; the company is headquartered in Abbott Park, Illinois, and was founded in 1888. Its diagnostics businesses include rapid and molecular diagnostics, point-of-care testing, laboratory and immunoassay systems, diabetes and continuous glucose monitoring technologies, and, following the 2026 acquisition of Exact Sciences, cancer diagnostics products including Cologuard and the Cancerguard multi-cancer screening test. Abbott’s medical devices portfolio includes cardiovascular, electrophysiology, structural heart, vascular, heart failure, neuromodulation and vision care products, while its nutrition business offers pediatric and adult nutrition, infant formula and medical nutrition products; its established pharmaceuticals segment markets branded generic medicines in international markets. In 2025 and 2026, Abbott advanced several major strategic changes, including entering into a definitive agreement to acquire Exact Sciences on November 19, 2025 and completing that acquisition on March 23, 2026 to expand into oncology diagnostics. The company also launched and received regulatory approvals for new electrophysiology offerings, including its Volt PFA System in the United States and CE Mark for the TactiFlex Duo Ablation Catheter, Sensor Enabled, in Europe, while beginning 2026 with a reorganization that combined its rapid, molecular and point-of-care diagnostics businesses into a single Rapid and Molecular Diagnostics segment and transferred the Amplatzer Amulet device from Structural Heart to Electrophysiology. Abbott further approved 2025 restructuring actions to streamline operations and reduce costs across Diagnostics, Nutritionals, Established Pharmaceuticals and Medical Devices, reflecting an ongoing operational efficiency program.